Investment Banking Services that Drive Transformative Transactions

Our experienced senior bankers provide expert M&A advisory services to health sciences firms and investors seeking superior outcomes.

200+

Deals Closed

20+

Transactions Per Year

100%

Health Sciences Transactions

M&A Advisory

We are part of the fabric of the industries we serve. As a global M&A investment banking advisory firm, our services are delivered by a team of experienced senior bankers who have spent their careers developing deep professional relationships and building in-depth knowledge of the companies, trends and insights relevant to our core areas of industry focus. 

M&A - Image

Proven Process

Crosstree executes against, “The Standard,” a system designed to set the bar for quality, consistency, and outcomes.

01

360° Storytelling

With a solid foundation of data and a deep understanding of your industry, we build a clear, elegant story of substance to explain your value to potential buyers. 

02

Marketing Strategy

We match your company’s distinguishing characteristics and unique value proposition with market trends and buyer/investor fit, using thoughtful, disciplined qualification and scoring rigor

03

Competitive Bidding

Our reputation as expert health sciences advisors with high quality deals increases potential buyer confidence and attention

04

Exceptional Outcomes

We consistently and predictably achieve spike valuations and exceptional financial results for our clients.

M&A - Process

Crosstree’s Client Outcomes Consistently Exceed Industry Benchmarks

Crosstree’s deep industry focus fosters efficient project execution. Our relationships with investors and strategic buyers are unmatched in the industry.

M&A - Higher Valuations

Achieve higher valuations

Our deals consistently achieve “spike valuations” through concise articulation of client value propositions, credible financial and technical support, and thoughtful alignment of industry trends.

M&A - Confident

Be confident in your success

Our culmination of industry expertise that leverages market data, trends, and a high-profile network, drives an outstanding closing rate of almost 90%.

M&A - Accelerate

Accelerate your closings

By combining technology, structured project management methodology, and a focused process approach, We close transactions faster — with less resourcing strain on clients — compared to traditional investment banks.

Client Testimonials

/ 3
Recent M&A Transactions
IPeople Acquired by RLDatix, a Portfolio Company of Five Arrows and TA Associates

IPeople Acquired by RLDatix, a Portfolio Company of Five Arrows and TA Associates

Deep 6 AI Acquired by Tempus 

Deep 6 AI Acquired by Tempus 

Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools

Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools

Actigraph, a Portfolio Company of Archimed, Acquired Biofourmis’ Life Science Business

Actigraph, a Portfolio Company of Archimed, Acquired Biofourmis’ Life Science Business

Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio

Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio

Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities

Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities